Lupus & antiphospholipid syndrome

Association between interstitial fibrosis/tubular atrophy (IFTA) on kidney biopsies and anti Ro60 antibody positivity in patients with lupus nephritis (LN)

LupusPublished Retrospective cohort study

Authors' conclusion

In this biopsy-based LN cohort, Ro60 positivity was associated with a consistent trend toward more severe IFTA, with a statistically significant association in sensitivity analysis excluding one severe outlier case.

Study context

Population
Adults with biopsy-confirmed LN at a single academic center
Participants
16 vs 25
Exposure
Ro60-positive vs Ro60-negative
  • Ro60-positiven = 16
  • Ro60-negativen = 25reference
Outcome
IFTA severity (none, mild, moderate, severe) graded by a renal pathologist
Methodological detailssingle-centre, ordinal logistic regression, multivariable proportional odds model
  • Single-centre
  • Ordinal logistic regression
  • Multivariable proportional odds model

Main finding

As reported in the abstract

IFTA severity (ordinal: none, mild, moderate, severe), Ro60 positivity
Ro60 positivityOdds ratio (95% CI)P value
Univariable analysis
3.05(0.86–11.5)
P = 0.087
Multivariable model, 29 complete cases
2.76(0.77–13.04)
P = 0.127

Observational data: associations, not effects.

Further findings

IFTA severity, Black race

OR (95% CI)P value
Black raceUnivariable analysis7.82 (1.02–93.12)P = 0.014
Black raceMultivariable model, 29 complete cases8.06 (0.92–275.61)P = 0.015

IFTA severity, class IV LN (multivariable)

OR (95% CI)P value
Class IV LN1.90 (0.37–13.24)P = 0.371

IFTA severity, sensitivity analysis excluding the single severe IFTA case

ORP value
Ro60 positivity5.25P = 0.028
Black race15.79P = 0.005

Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.

Original publication

Association between interstitial fibrosis/tubular atrophy (IFTA) on kidney biopsies and anti Ro60 antibody positivity in patients with lupus nephritis (LN). Lupus. Published 16 April 2026. doi:10.1177/09612033261443602

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.